search
Back to results

Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis

Primary Purpose

Knee Osteoarthritis

Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
glucosamine sulfate /chondroitin sulfate - capsules
glucosamine sulfate /chondroitin sulfate - sachet
Cosamin DS®
Sponsored by
Ache Laboratorios Farmaceuticos S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis focused on measuring Knee Osteoarthritis;, Glucosamine;, Chondroitin.

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patient, older than 40 years of age, with knee osteoarthritis, based on clinical and radiological criteria (Kellgren-Lawrence grade 2 - 3), as specified:

    1. Pain on movement of the affected knee for more than 15 days in the previous month with at least partial relief at rest;
    2. Presence of osteophytes at least 1 mm in radiological imaging;
  • Knee osteoarthritis symptoms for at least six months prior to randomization.

Exclusion Criteria:

  • Concomitant arthropathy that may confuse or interfere with assessing the efficacy or pain;
  • Patellar disease isolated, with primary symptoms of pain in the anterior knee, in the absence of radiological findings already described;
  • History of significant injury on collateral ligament, or anterior cruciate, or meniscus of the joint studied, with surgery, or immobilization for at least 3 weeks;
  • Arthroscopy of the affected knee in last 6 months;
  • Serum creatinine ≥ 1.8 mg/dL;
  • Diagnosis of diabetes mellitus;
  • Presence of any serious disease that could compromise the study, at the investigator discretion;
  • History of adverse event or allergy to acetaminophen, glucosamine sulfate or chondroitin sulfate;
  • Inability to understand and report the study questionnaire and the Visual Analogic Scale;
  • Inability to understand and consent to participate in this clinical study, expressed by signing the Informed Consent (IC);
  • Woman in pregnancy.
  • If female of childbearing potential, has a negative urine pregnancy test at Visit 0 and do not use, or do not agree to use, for the duration of the study, a medically acceptable form of contraception as determined by the investigator;
  • Alcohol intake ( > 3 doses/day);
  • Oral or intramuscular corticosteroids four weeks prior to study entry;
  • Intra-articular injections with corticosteroids, into the studied knee, within the past three months;
  • Intra-articular injections in any other joint within the past four weeks;
  • NSAID users that don´t respect the washout period. Low-dose aspirin (325 mg or less, once daily) is allowed for cardio-protective benefit;
  • Intra-articular injections of hyaluronic acid within the past 12 months;
  • Use of topical analgesic in the joint studied or any other oral analgesic (with the exception of acetaminophen and other NSAID) two weeks prior to randomization;
  • Implementation of any other medical treatment for osteoarthritis one month prior to study entry;
  • Participation in last one year of clinical protocols, unless it can be direct benefit to patient;
  • Use of glucosamine and/or chondroitin sulfate three and six months prior the study entry, respectively;
  • Initiation of physical therapy two months prior to the study period;
  • Use of tetracycline and oral anticoagulants;
  • Use of vitamin D in doses in doses above the recommended;
  • Patients in alternative therapies;
  • Allergy to sulfonamides;
  • Presence of psychiatric disorders that could compromise the study.

Sites / Locations

  • Serviço de reumatologia do hospital e maternidade celso pierro da PUC-Campinas

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

glucosamine sulfate /chondroitin sulfate capsule

glucosamine sulfate /chondroitin sulfate - sachet

Cosamin DS®

Arm Description

500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.

1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.

500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.

Outcomes

Primary Outcome Measures

Change from baseline in pain intensity in the affected knee and variation of Lequesne's index and VAS at week 16 .

Secondary Outcome Measures

Percentage of Participants with any Decrease in Pain Visual Analogue Scale (VAS)

Full Information

First Posted
July 19, 2013
Last Updated
December 10, 2013
Sponsor
Ache Laboratorios Farmaceuticos S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT02010918
Brief Title
Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis
Official Title
A Phase III, Multicenter, Randomized, Parallel, Open Label and Comparative Study to Evaluate the Efficacy of 500 mg Glucosamine Sulfate (GS) / 400 mg Chondroitin Sulfate (CS)Capsules and 1500 mg GS / 1200 mg CS Sachet Compared With Cosamin DS® Capsule in Treatment of Knee Osteoarthritis..
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
November 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ache Laboratorios Farmaceuticos S.A.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether 500 mg Glucosamine Sulfate / 400 mg Chondroitin Sulfate Capsules and 1500 mg Glucosamine Sulfate / 1200 mg Chondroitin Sulfate Sachet is effective and safe compared Cosamin DS ® Capsule in Treatment of Knee Osteoarthritis.
Detailed Description
The Groups receive treatment for 16 weeks. The study is realized in 16 sites in Brazil.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis
Keywords
Knee Osteoarthritis;, Glucosamine;, Chondroitin.

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
922 (Actual)

8. Arms, Groups, and Interventions

Arm Title
glucosamine sulfate /chondroitin sulfate capsule
Arm Type
Experimental
Arm Description
500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
Arm Title
glucosamine sulfate /chondroitin sulfate - sachet
Arm Type
Experimental
Arm Description
1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
Arm Title
Cosamin DS®
Arm Type
Active Comparator
Arm Description
500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
Intervention Type
Drug
Intervention Name(s)
glucosamine sulfate /chondroitin sulfate - capsules
Intervention Description
500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
Intervention Type
Drug
Intervention Name(s)
glucosamine sulfate /chondroitin sulfate - sachet
Intervention Description
1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
Intervention Type
Drug
Intervention Name(s)
Cosamin DS®
Intervention Description
500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
Primary Outcome Measure Information:
Title
Change from baseline in pain intensity in the affected knee and variation of Lequesne's index and VAS at week 16 .
Time Frame
BASELINE, week 16
Secondary Outcome Measure Information:
Title
Percentage of Participants with any Decrease in Pain Visual Analogue Scale (VAS)
Time Frame
baseline, week 16
Other Pre-specified Outcome Measures:
Title
Number of Participants with Serious and Non-Serious Adverse Events
Time Frame
baseline, week 16

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient, older than 40 years of age, with knee osteoarthritis, based on clinical and radiological criteria (Kellgren-Lawrence grade 2 - 3), as specified: Pain on movement of the affected knee for more than 15 days in the previous month with at least partial relief at rest; Presence of osteophytes at least 1 mm in radiological imaging; Knee osteoarthritis symptoms for at least six months prior to randomization. Exclusion Criteria: Concomitant arthropathy that may confuse or interfere with assessing the efficacy or pain; Patellar disease isolated, with primary symptoms of pain in the anterior knee, in the absence of radiological findings already described; History of significant injury on collateral ligament, or anterior cruciate, or meniscus of the joint studied, with surgery, or immobilization for at least 3 weeks; Arthroscopy of the affected knee in last 6 months; Serum creatinine ≥ 1.8 mg/dL; Diagnosis of diabetes mellitus; Presence of any serious disease that could compromise the study, at the investigator discretion; History of adverse event or allergy to acetaminophen, glucosamine sulfate or chondroitin sulfate; Inability to understand and report the study questionnaire and the Visual Analogic Scale; Inability to understand and consent to participate in this clinical study, expressed by signing the Informed Consent (IC); Woman in pregnancy. If female of childbearing potential, has a negative urine pregnancy test at Visit 0 and do not use, or do not agree to use, for the duration of the study, a medically acceptable form of contraception as determined by the investigator; Alcohol intake ( > 3 doses/day); Oral or intramuscular corticosteroids four weeks prior to study entry; Intra-articular injections with corticosteroids, into the studied knee, within the past three months; Intra-articular injections in any other joint within the past four weeks; NSAID users that don´t respect the washout period. Low-dose aspirin (325 mg or less, once daily) is allowed for cardio-protective benefit; Intra-articular injections of hyaluronic acid within the past 12 months; Use of topical analgesic in the joint studied or any other oral analgesic (with the exception of acetaminophen and other NSAID) two weeks prior to randomization; Implementation of any other medical treatment for osteoarthritis one month prior to study entry; Participation in last one year of clinical protocols, unless it can be direct benefit to patient; Use of glucosamine and/or chondroitin sulfate three and six months prior the study entry, respectively; Initiation of physical therapy two months prior to the study period; Use of tetracycline and oral anticoagulants; Use of vitamin D in doses in doses above the recommended; Patients in alternative therapies; Allergy to sulfonamides; Presence of psychiatric disorders that could compromise the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José R Provenza, MD
Organizational Affiliation
Pontifícia Universidade Católica de Campinas, São Paulo, Brazil
Official's Role
Principal Investigator
Facility Information:
Facility Name
Serviço de reumatologia do hospital e maternidade celso pierro da PUC-Campinas
City
Campinas
State/Province
São Paulo
ZIP/Postal Code
13330-260
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis

We'll reach out to this number within 24 hrs